SCHEMBL2696157

SCHEMBL2696157

CCCC[C@H](C(=O)O)n1c(=O)c2cnccc2n(C(C)c2c[nH]c3cccc(C)c23)c1=O

nearest known ligand 0.60

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 20/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2696160 1.00 CMA1 (0.60) CMA1
SCHEMBL2697494 0.95 CMA1 (0.59) CMA1
SCHEMBL2697487 0.95 CMA1 (0.59) CMA1
SCHEMBL3688465 0.89 CMA1 (0.48) CMA1
SCHEMBL3685360 0.89 CMA1 (0.48) CMA1
SCHEMBL3682510 0.89 CMA1 (0.48) CMA1
SCHEMBL3682608 0.85 CMA1 (0.43) CMA1
SCHEMBL3684412 0.85 CMA1 (0.43) CMA1
SCHEMBL3682606 0.85 CMA1 (0.43) CMA1
SCHEMBL3681840 0.84 CMA1 (0.47) CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501749-B2 Azaquinazolinediones chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-08-06 — — US disclosed
EP-2391624-B1 AZAQUINAZOLINEDIONES USEFUL AS CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2013-01-16 — — EP disclosed
US-20120108597-A1 Azaquinazolinediones Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-03 — — US disclosed
EP-2391624-A1 AZAQUINAZOLINEDIONES USEFUL AS CHYMASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2011-12-07 — — EP disclosed
WO-2010088195-A1 AZAQUINAZOLINEDIONES USEFUL AS CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108597-A1 Azaquinazolinediones Chymase Inhibitors CMA1, SERPINB1, CTSC CMA1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback